Deadline Alert: Grail, Inc. (GRAL) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Grail, Inc. (NASDAQ: GRAL) faces a class action securities fraud lawsuit after failing to meet the primary endpoint in its NHS-Galleri cancer trial on February 19, 2026. The announcement caused the stock to plummet 50.5%. Investors allege the company made materially false statements about trial results and failed to disclose that the three-year timeline was insufficient to demonstrate the primary endpoint, misleading shareholders about business prospects.

07/13/2026, 1:52 PM • GlobeNewswire

Jeff Bezos Backed Grail Before It Lost Half Its Value. Here's Whether He Was Early -- or Just Wrong.

Grail's stock crashed 50% in February after its NHS-Galleri multi-cancer early detection test failed to meet its primary endpoint of reducing late-stage cancer detection. However, the stock has partially recovered on optimism about favorable results in 12 specific cancer types. The company's future depends on FDA approval and insurer adoption, which will hinge on cost-benefit analyses by medical insurers.

07/13/2026, 7:15 AM • The Motley Fool

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – PODD

Rosen Law Firm has filed class action lawsuits on behalf of investors in Insulet Corporation (PODD), GRAIL, Inc. (GRAL), and GeneDx Holdings Corp. (WGS). The lawsuits allege that defendants made false or misleading statements regarding manufacturing controls, product safety compliance, and regulatory risks. Investors who purchased securities during the specified class periods may be eligible for compensation. The lead plaintiff deadline is August 31, 2026.

07/11/2026, 7:11 PM • GlobeNewswire

ROSEN, A TOP RANKED LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The company allegedly concealed that the trial period was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be eligible for compensation. The lead plaintiff deadline is August 4, 2026.

07/11/2026, 7:03 PM • GlobeNewswire

GRAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

A federal securities class action has been filed against Grail, Inc. (NASDAQ: GRAL) alleging that company executives made false and misleading statements about the NHS-Galleri cancer detection trial's likelihood of success while concealing material adverse facts. On February 19, 2026, Grail announced the trial failed to achieve its primary endpoint, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

07/11/2026, 8:50 AM • GlobeNewswire

INVESTOR REMINDER: Berger Montague Notifies GRAIL, Inc. (NASDAQ: GRAL) Investors of a Class Action Lawsuit and Deadline

Berger Montague has filed a class action lawsuit against GRAIL, Inc. on behalf of investors who purchased stock between May 13, 2025 and February 19, 2026. The lawsuit alleges that GRAIL failed to disclose that the NHS-Galleri trial was insufficient to demonstrate the primary endpoint of reducing Stage III-IV cancers. On February 19, 2026, GRAIL announced the trial's primary endpoint had not been met, causing the stock to plummet approximately 50.55% in a single trading day from $101.53 to $50.21 per share. The lead plaintiff deadline is August 4, 2026.

07/10/2026, 9:46 AM • GlobeNewswire

ROSEN, A LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

A securities class action lawsuit has been filed against GRAIL, Inc. alleging that defendants made materially false and misleading statements regarding their NHS-Galleri trial results. The complaint claims defendants provided overly positive statements while concealing material adverse facts about the trial's ability to demonstrate a reduction in Stage III-IV cancers. Investors who purchased GRAIL common stock between May 13, 2025 and February 19, 2026 may be entitled to compensation. The lead plaintiff deadline is August 4, 2026.

07/08/2026, 11:23 PM • GlobeNewswire

MEGAN HOLDINGS LIMITED (MGN) INVESTOR ALERT Investors With Large Losses in Megan Holdings Limited Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Bernstein Liebhard LLP has announced multiple securities class action lawsuits against Megan Holdings Limited (MGN), Photronics, Inc. (PLAB), and GRAIL, Inc. (GRAL). The lawsuits allege that defendants made materially false and misleading statements regarding their businesses and operations, causing securities to trade at artificially inflated prices. Investors who suffered losses during the respective class periods are encouraged to contact the firm.

07/08/2026, 3:53 PM • GlobeNewswire

GRAIL, Inc. (GRAL) Faces Securities Class Action Amid NHS-Galleri Trial Failure, $2.2B Market Cap Wipeout – HBSS

GRAIL, Inc. lost over $2.2 billion in market capitalization on February 20, 2026, after its NHS-Galleri trial failed to meet its primary endpoint for early cancer detection. A securities class action lawsuit alleges the company misled investors about the trial's design and likelihood of success, claiming management knew a three-year follow-up period would be insufficient but expressed high confidence anyway. The stock plunged over 50% following the announcement.

07/08/2026, 2:43 PM • GlobeNewswire

Bragar Eagel & Squire, P.C. Reminds GRAIL, Inc. Investors They Have Until August 4th to Contact the Firm Seeking Lead Plaintiff Role

A class action lawsuit has been filed against GRAIL, Inc. alleging the company provided materially false and misleading statements regarding its NHS Galleri multi-cancer screening trial. The complaint claims GRAIL concealed that the trial was insufficient to demonstrate reduction in Stage III-IV cancers and failed to disclose detailed results. On February 19, 2026, GRAIL announced the trial's primary endpoint was not achieved, causing significant stock price decline. Investors who purchased GRAIL shares between May 13, 2025, and February 19, 2026, have until August 4, 2026, to apply as lead plaintiff.

07/07/2026, 2:58 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Badger Meter, Inc. (BMI), Grail, Inc. (GRAL), and PicS N.V.  (PICS) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against Badger Meter, Grail, Inc., and PicS N.V. The lawsuits allege materially false statements and/or failure to disclose material facts. Badger Meter faces allegations regarding order pull-forward practices, Grail regarding its NHS-Galleri trial, and PicS regarding credit evaluation procedures in its IPO. Investors who suffered losses during the relevant periods are encouraged to seek lead plaintiff status.

07/07/2026, 2:31 PM • GlobeNewswire

GRAIL, Inc. (GRAL) Securities Class Action Filed Following NHS-Galleri Trial Failure and $2.2 Billion Market Cap Loss -- HBSS

GRAIL, Inc. faced a securities class action lawsuit after its NHS-Galleri trial failed to meet its primary endpoint on February 20, 2026, resulting in a $2.2 billion market capitalization loss and over 50% stock price decline. The lawsuit alleges GRAIL misled investors about the trial's design and likelihood of success, with the company later admitting it should have allowed for a longer follow-up period than the three years originally touted.

07/06/2026, 5:25 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against GRAIL, Inc. alleging that company executives made materially false and misleading statements regarding the NHS-Galleri trial's likelihood of success. The complaint claims defendants misrepresented the trial's prospects and concealed adverse data trends, with the class period spanning May 13, 2025 to February 19, 2026. Investors have until August 4, 2026 to request lead plaintiff status.

07/06/2026, 12:00 PM • GlobeNewswire

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages GRAIL, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – GRAL

Rosen Law Firm is reminding investors who purchased GRAIL, Inc. common stock between May 13, 2025 and February 19, 2026 of an important August 4, 2026 lead plaintiff deadline in an ongoing securities class action. The lawsuit alleges that GRAIL provided overwhelmingly positive statements while concealing material adverse facts about its NHS-Galleri trial, specifically that the trial period was insufficient to demonstrate the achievability of reducing Stage III-IV cancers and that the company refused to provide detailed results.

07/05/2026, 10:54 PM • GlobeNewswire

GRAL CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Grail (GRAL) Investors of Securities Class Action Lawsuit Deadline on August 4, 2026

Faruqi & Faruqi, LLP is investigating securities fraud claims against Grail, Inc. (NASDAQ: GRAL) for allegedly making false and misleading statements about its NHS-Galleri cancer detection trial. The company touted confidence in the trial's success while concealing that the three-year trial period was insufficient to achieve its primary endpoint. On February 19, 2026, Grail announced the primary endpoint was not met, causing the stock to plummet 50.55% in a single day from $101.53 to $50.21 per share. Investors who purchased GRAL stock between May 13, 2025 and February 19, 2026 may be eligible to participate in the class action, with a deadline of August 4, 2026 to seek lead plaintiff appointment.

07/05/2026, 9:49 AM • GlobeNewswire